Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-10-14
1997-01-14
Patterson, Jr., Charles L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530380, 530395, 424 9463, 424 9464, 128899, C07K 14705, C07K 14745, A61K 3817, A61K 3836
Patent
active
055939597
ABSTRACT:
The subject invention provides purified polypeptides encoded by naturally-occurring wild-type platelet glycoprotein Ib alpha having a mutation which renders the polypeptide more reactive with von Willebrand factor. Preferably, the mutation is in the hinge region of GP Ib.alpha., such as the substitution of valine for glycine at residue 233. These mutations alter the three-dimensional structure of the mutant polypeptide from a beta bend conformation to an alpha helix formation, and also create an amphipathic region within the mutant polypeptide. DNA encoding the mutant polypeptides, as well as expression systems for the production of the mutant polypeptides, are also provided. Methods and compositions using the mutant polypeptides and DNA oligomers complementary to the mutant polypeptides are further provided.
REFERENCES:
J. L. Miller et al. "Patients with Platelet-type von Willebrand . . . " Circulation 82(4 Suppl. 3) III 595 (1990).
J. L. Miller et al. "Mutation in the Gene Encoding the .alpha.-chain . . . " Proc. Natl. Acad. Sci. 88:4761-4765 (Jun. 1991).
R. I. Handin et al. Blood. 74:129a (1989).
A. Wicki et al. "The Glycoprotein Ib Complex of Human Blood Platelets" Eur. J. Biochem 163:43-50 (1987).
V. A. Canfield et al. "Isolation and Characterization of the .alpha. and .beta.. . . " Biochem. Biophys. Res. Commun. 147(2)526-534 (Sep. 1987).
J. L. Miller et al. "von Willebrand Factor Binds to Platelets . . . " J. Clin. Invest. 72:1532-1542 (Nov. 1983).
J. N. George et al. "Molecular Defects in Interactions of Platelets . . . " New. Engl. J. Med. 311(17)1084-1098 (Oct. 1984).
S. D. Russell and G. J. Roth, Blood 81: 1787-1791 (1993).
Max Vasquez, et al., "Helix-Coil Transition Theory Including Long-Range Electrostatic Interactions: Application to Globular Proteins", Biopolymers 26: 351-371 (1987).
James M. Chen, et al., "Conformations of the central transforming region (Ile 55-Met 67) of the p21 protein and their relationship to activation of the protein", Int. J. Peptide Res. 36; 247-254 (1990).
James Chen, et al., "Comparative X-ray Crystallographic Evidence for a .beta.-Bend Conformation as the Active Structure for Peptide T in T4 Receptor Recognition", Journal of Protein Chemistry, 8: 87-100 (1989).
Matthew R. Pincus, "The Chain Build-Up Procedure in Computing the Structures of Biologically Active Polypeptides and Proteins", International Journal of Quantum Chemistry: Quantum Biology Symposium, 15: 209-220 (1988).
Dipak Shah, et al., "Correlation of .beta.-bend conformations of tetrapeptides with their activities in CD4-receptor binding assays", Int. J. Peptide Protein Res. 34: 325-332 (1989).
James M. Chen, et al., "Comparison of the Predicted Structure for the Activated Form of the P21 Protein with the X-ray Crystal Structure", Journal of Protein Chemistry 9: 543-547 (1990).
Cunningham David
Finch Clara N.
Lyle Vicki A.
Miller Jonathan L.
Pincus Matthew R.
Patterson Jr. Charles L.
Prouty Rebecca
The Research Foundation of State University of New York
LandOfFree
Mutations in the gene encoding the alpha chain of platelet glyco does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutations in the gene encoding the alpha chain of platelet glyco, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutations in the gene encoding the alpha chain of platelet glyco will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1388157